Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes

The diverse barriers we identified underscore the need for better patient-prescriber communication to ensure that newly prescribed injectable medications are consistent with a patient's ability or willingness to manage them, to appropriately set expectations about medications, and to address new barriers that arise during the course of treatment.